The Trendlines Group Reports 2016 Third Quarter Results

Wednesday, 09 November 2016 08:00 AM

MISGAV, ISRAEL AND SINGAPORE / ACCESSWIRE / November 9, 2016 / The Trendlines Group Ltd. (the "Company" and together with its subsidiaries and associated companies, the "Group") an Israeli company focused on developing technology-based companies in the medical and agricultural fields, announced its financial results for the three months ended 30 September 2016 ("3Q201").

Third Quarter 2016 Highlights:

Portfolio

  • Fair value of portfolio is US$83.6 million after completion of the sale of its shareholding in E.T. View Medical Ltd. ("E.T. View")
  • 3 new companies started during the quarter, bringing the total of new portfolio companies invested to date in 2016 to six
  • A gain of approximately US$1.1 million in the fair value of the Most Valuable Portfolio Company was recorded due to commercial progress
  • 6 portfolio companies complete successful follow-on funding
  • CE Mark approval received by Gordian Surgical Ltd. and CoreBone Ltd.
  • EdenShield Ltd. receives U.S. patent

Group Financials

  • Trendlines reports total income of US$4.1 million for Q32016, compared to loss of US$0.2 million in the three months ended 2015 ("Q32015")
  • Trendlines completed the sale of E.T. View for total net proceeds of US$3.5 million, which was received subsequent to the financial period
  • Trendlines received US$0.9 million dividend from the Most Valuable Portfolio Company which increased the Group's cash balance, but had no impact on Group earnings
  • Net income totaled US$1.6 million in Q32016 compared to a loss of US$3.4 million in Q32015
  • Total current assets increased to US$20.4 million, an increase of US$1.7 million from 30 June 2016

Corporate/Business Development

  • Trendlines signs MOU with B. Braun for co-investment in Trendlines Medical Singapore, which is expected to be operational by end of 2016
  • Trendlines ADRs start trading on OTCQX International Market
  • Head of R&D at Trendlines' partner, Bayer Crop Science, gives keynote speech at Trendlines' AgriVest Conference to investors and experts from 20 countries, including investors, brokers, analysts and journalists from Singapore
  • Steve Rhodes and Todd Dollinger delivered irrevocable instructions to purchase Trendlines shares, irrespective of share price, beginning December 2016 for a 12-month period.

2016 Third Quarter Financial Results:

"We saw good financial performance in the third quarter of 2016," said Steve Rhodes, Chairman and CEO of Trendlines. "We were particularly pleased with both the completion of the sale of E.T. View to the Danish medical device company, Ambu A/S, and with the large dividend payment we received from our Most Valuable Portfolio Company as they met a significant milestone under their agreement with the purchaser of their technology."

For the third quarter of 2016, Total Income was US$4.1 million, compared to a loss of US$2.9 million in the second quarter of 2016, and a loss of approximately US$0.2 million in the third quarter of 2015. The increase in Total Income for the quarter is largely a result of the gain of US$2.1 from the completion of the sale of the shareholdings in E.T. View. The increase in the third quarter income also reflects the US$0.6 million gain from the change in the fair value ("Portfolio Value") of Trendlines' portfolio companies, which compares to a loss of approximately US$4.7 million in the second quarter of 2016 and a loss of about US$1.0 million in the third quarter of 2015. Total Portfolio Value after the sale of E.T. View was US$83.6 million.

Operating, general and administrative expenses were US$2.1 million in the third quarter of 2016, compared to US$2.3 million in the second quarter of 2016, and US$1.8 million in third quarter of 2015. Operating, general and administrative expenses in the third quarter of 2016 were US$0.3 million higher than in the third quarter of 2015, mainly due to higher professional expenses incurred as a result of Trendlines' public listing in Singapore (SGX: 42T) in November 2015.

Net income for the third quarter of 2016 was approximately US$1.6 million, compared to a loss of US$4.6 million in the second quarter of 2016 and a net loss of US$3.4 million in the third quarter of 2015.

Current assets rose US$1.7 million in the third quarter to US$20.4 million from US$18.7 million as of 30 June 2016. Total current assets as at 31 December 2015 were US$24 million.

The fair value of all the portfolio companies was approximately US$83.6 million as at 30 September 3016. This compares with the adjusted portfolio value at 31 December 2015 of US$85.8 million, which includes the fair market value of Trendlines' associated company E.T. View which was sold in the third quarter of 2016 and, as a result, does not appear in the Portfolio Value as at 30 September 2016. The table below shows a pro-forma calculation of the fair value of the portfolio including the recent exit value of E. T. View plus the dividend received from the Most Valuable Portfolio Company, both of which occurred in the third quarter of 2016 and had the effect of reducing the portfolio value.

Fair Value of Portfolio (US$ million)

   
30 Sept. 2016
   
31 Dec. 2015
Investments in Portfolio Companies/ Portfolio Value
(Reported)
  83.6     84.5
Investments in Portfolio Companies/ Portfolio Value
(Pro-Forma)
  88.0*     85.8**

*Including exit value of E.T. View and dividend payment from Most Valuable Portfolio Company received in Q32016

**Including market value of E.T. View at 31 December 2015 of US$1.5 million, reported based on equity method for financial reporting purposes

Commenting on portfolio company developments during the quarter, Chairman and CEO, Todd Dollinger, said: "I am pleased to report excellent regulatory and clinical developments in a number of our portfolio companies over the quarter. Among regulatory successes, Gordian Surgical Ltd. received CE Mark approval for its TroClose1200™, CoreBone Ltd. also received CE Mark approval for its innovative bioactive bone graft material; Eden Shield Ltd. received a U.S. patent for its nontoxic pest control solution. Among companies reporting clinical progress, ApiFix Ltd. reached a 100-patient milestone and OrthoSpin Ltd. launched its first human clinical trials at Galilee Medical Center in Israel."

Mr. Dollinger concluded: "We have also made significant progress with the establishment of Trendlines Medical Singapore, where we appointed Eric Loh, a veteran in the medical device sector, as CEO in September. Trendlines Singapore also signed an MOU with shareholder B. Braun Melsungen AG for investment in the new entity, as well as for support of the portfolio companies in technological development, regulatory, medical, scientific affairs, and marketing and sales. We look forward to updating our shareholders on progress in Singapore as we move ahead with developments there, and will continue to provide updates on other near-term events as we approach year-end."

Quarterly Conference Call and Webcast

Trendlines will host a conference call to discuss the 2016 third quarter results on Wednesday, November 9th 3:00pm Singapore time, 9:00am in Israel. A live webcast of the conference call, together with a slide presentation that includes supplemental financial information, will be accessible through the company's Investor Relations website at http://investors.trendlines.com. In addition, an archive of the webcast will be accessible for 90 days through the same link.

About The Trendlines Group

The Trendlines Group is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. The Trendlines Group is traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX® International (OTCQX: TRNLY).

Forward-Looking Statement

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the Company's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," to be uncertain and forward looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission.

Investor Contact Information

Israel
Judith Kleinman, Director, Investor Relations & Corporate Communications
[email protected]
+972.72.260.7000

US
Adam Holdsworth, Managing Director of Investor Relations
[email protected]
646-862-4607

The Trendlines Group
Consolidated Statement of Comprehensive Income

   
Group
   
Group
 
   
Three Months Ended
   
Nine Months Ended
 
   
30 September
2016
(Unaudited)
   
30 September
2015
(Unaudited)
   
30 September
2016
(Unaudited)
   
30 September
2015
(Unaudited)
 
   
US$'000
   
US$'000
   
US$'000
   
US$'000
 
                         
INCOME
                       
Gain (loss) from change in fair value of investments in portfolio companies
    643       (951 )     (5,049 )     4,723  
Income from services to portfolio companies
    1,032       998       3,176       3,223  
Group's share of losses of companies accounted for under the equity method
    -       (187 )     -       (315 )
Gain from disposal of investment accounted for under the equity method
    2,089       -       2,089       -  
Income from contracted R&D services
    194       190       832       384  
Financial income
    15       (380 )     982       330  
Other income
    108       114       284       435  
                                 
Total income
    4,081       (216 )     2,314       8,780  
                                 
EXPENSES
                               
Operating, general and administrative expenses
    2,081       1,823       6,469       4,975  
Marketing expenses
    41       50       201       199  
R&D expenses, net
    258       148       640       432  
Financial expenses
    33       1,396       297       1,478  
                                 
Total expenses
    2,413       3,417       7,607       7,084  
                                 
Income (loss) before income taxes
    1,668       (3,633 )     (5,293 )     1,696  
Income tax expenses /(benefit)
    106       (248 )     (1,475 )     1,731  
                                 
Net income (loss)
    1,562       (3,385 )     (3,818 )     (35 )
                                 
Other comprehensive income to be reclassified to profit or loss in subsequent periods:
                               
Gain from cash flow hedges
    48       -       48       -  
                                 
Total other comprehensive income
    48       -       48       -  
                                 
Total comprehensive income (loss)
    1,610       (3,385 )     (3,770 )     (35 )

 

 

The Trendlines Group
Consolidated Statement of Comprehensive Income (continued)

 

Net income (loss) attributable to:
                       
Equity holders of the Company
    1,562       (3,361 )     (3,818 )     229  
Non-controlling interests
    -       (24 )     -       (264 )
                                 
      1,562       (3,385 )     (3,818 )     (35 )

 

Total comprehensive income attributable to:
                       
Equity holders of the Company
    48       -       48       -  
Non-controlling interests
    -       -       -       -  
                                 
      48       -       48       -  
                                 
Net earnings (loss) per share attributable to equity holders of the Company (U.S. dollars):
                               
                                 
Basic net earnings (loss)
    0.00       (0.01 )     (0.01 )     0.00  
Diluted net earnings (loss)
    0.00       (0.01 )     (0.01 )     0.00  

 

The Trendlines Group
Condensed Consolidated Balance Sheet

   
30 September
2016
   
31 December
2015
 
   
(Unaudited)
   
(Audited)
 
   
US$'000
   
US$'000
 
ASSETS
           
             
Current assets
           
Cash and cash equivalents
    5,113       6,998  
Restricted short-term deposits
    171       396  
Short-term investments
    11,033       16,042  
Accounts and other receivables
    3,960       428  
Short-term loans to portfolio companies
    134       136  
                 
      20,411       24,000  
                 
Non-current assets
               
Investment in subsidiaries
    -       -  
Investments in portfolio companies
    83,566       84,447  
Property, plant and equipment, net
    603       541  
                 
      84,169       84,988  
                 
Total assets
    104,580       108,988  
EQUITY AND LIABILITIES
               
                 
Current liabilities
               
Trade and other payables
    970       1,078  
Deferred revenues
    2,652       2,579  
                 
      3,622       3,657  
                 
Non-current liabilities
               
Deferred revenues
    1,222       713  
Loans from the Israel's Chief Scientist
    4,348       4,449  
Deferred taxes, net
    14,379       15,959  
Other long-term liabilities
    14       52  
                 
      19,963       21,173  
                 
Total liabilities
    23,585       24,830  

 

The Trendlines Group
Condensed Consolidated Balance Sheet (continued)

EQUITY
           
Equity attributable to equity holders of the company:
           
Share capital
    1,315       1,315  
Share premium
    54,863       54,852  
Reserve from share-based payment transactions
    4,799       4,203  
Reserve from hedges
    48       -  
Retained earnings
    19,936       23,754  
                 
Equity attributable to owners of the parent
    80,961       84,124  
Non-controlling interests
    34       34  
                 
Total equity
    80,995       84,158  
                 
Total equity and liabilities
    104,580       108,988  

 

The Trendlines Group
Consolidated Statement of Cash Flow

   
Three Months Ended
   
Nine Months Ended
 
   
30 September
   
30 September
   
30 September
   
30 September
 
   
2016
(Unaudited)
   
2015
(Unaudited)
   
2016
(Unaudited)
   
2015
(Unaudited)
 
   
US$'000
   
US$'000
   
US$'000
   
US$'000
 
CASH FLOWS FROM OPERATING ACTIVITIES
                       
                         
Net income(loss)
    1,562       (3,385 )     (3,818 )     (35 )
Adjustments to reconcile net income (loss) to net cash used in operating activities
                               
                                 
Adjustments to the profit or loss items:
                               
                                 
Depreciation
    25       29       77       81  
Income tax expense /(benefit)
    106       (248 )     (1,475 )     1,731  
(Gain) loss from changes in fair value of investments in portfolio companies
    (643 )     951       5,049       (4,723 )
Investments in portfolio companies
    (667 )     (705 )     (2,873 )     (1,033 )
Financial income (expense), net
    (9 )     1,171       (747 )     498  
Income from services to portfolio companies
    (961 )     (964 )     (2,991 )     (3,064 )
Share-based payments
    174       340       607       1,187  
Group's share of losses of companies accounted for under the equity method, net
    -       187       -       315  
Gain from disposal of investment accounted for under the equity method
    (2,089 )     -       (2,089 )     -  
                                 
Changes in asset and liability items:
                               
(Increase) decrease in short-term loans
    (77 )     49       (20 )     (7 )
Decrease (increase) in accounts and other receivables
    65       (238 )     48       195  
(Decrease) increase in trade and other payables
    (275 )     230       (108 )     (372 )
(Decrease) increase in other long-term liabilities
    (37 )     31       (38 )     31  
                                 
      (4,388 )     833       (4,560 )     (5,161 )
Cash (paid) received during the period for:
                               
Taxes paid
    (106 )     -       (106 )     -  
Dividend received
    897       -       897       718  
Interest received
    17       -       90       -  
Interest paid
    -       -       -       (54 )
                                 
      808       -       881       664  
                                 
Net cash used in operating activities
    (2,018 )     (2,552 )     (7,497 )     (4,532 )

 

The Trendlines Group
Consolidated Statement of Cash Flow (continued)

   
Three Months Ended
   
Nine Months Ended
 
   
30 September
   
30 September
   
30 September
   
30 September
 
   
2016
(Unaudited)
   
2015
(Unaudited)
   
2016
(Unaudited)
   
2015
(Unaudited)
 
   
US$'000
   
US$'000
   
US$'000
   
US$'000
 
CASH FLOWS FROM INVESTING ACTIVITIES
                       
Purchase of property, plant and equipment
    (96 )     (5 )     (139 )     (26 )
Purchase of shares and warrants of investments in companies accounted for under the equity method
    -       -       -       (194 )
(Purchase of) proceeds from sale of short-term investments, net
    (11,017 )     -       5,036       292  
Redemption of (increase in) restricted deposits, net
    160       (4,486 )     225       (4,656 )
                                 
Net cash (used in) provided by investing activities
    (10,953 )     (4,491 )     5,122       (4,584 )
                                 
CASH FLOWS FROM FINANCING ACTIVITIES
                               
Issuance of shares, net
    -       -       -       2,118  
Issuance of convertible debentures, net
    -       507       -       10,171  
Deferred IPO costs
    -       (1,164 )     -       (1,513 )
Loans from Israel's Chief Scientist
    314       -       490       -  
Repayment of convertible debentures
    -       -       -       (53 )
                                 
Net cash (used in) provided by financing activities
    314       (657 )     490       10,723  
                                 
Increase (decrease) in cash and cash equivalents
    (12,657 )     (7,700 )     (1,885 )     1,607  
Cash and cash equivalents at the beginning of the period
    17,770       10,843       6,998       1,536  
                                 
Cash and cash equivalents at the end of the period
    5,113       3,143       5,113       3,143  
                                 
Significant non-cash transactions
                               
                                 
Conversion of convertible debentures into shares
    -       -       -       706  
                                 
Acquisition of non-controlling interest by issuance of shares
    -       -       -       2,100  
                                 
Exercise of options
    -       -       11       -  
                                 
Receivable in respect of sale of portfolio company and of shares held under equity method
    3,531       -       3,531       -  

SOURCE: The Trendlines Group